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A-740003a b s t r a c t
The P2X7R is a functionally distinct member of the P2X family of non-selective cation channels associated
with rapid activation of the inﬂammasome complex and signalling interleukin (IL)-1b release in macro-
phages. The main focus of this investigation was to compare P2X7R-driven IL-1 production by primary
murine bone marrow derived dendritic cells (BMDC) and macrophages (BMM). P2X7R expression in mur-
ine BMDC and BMM at both transcriptional (P2X7A variant) and protein levels was demonstrated.
Priming with lipopolysaccharide (LPS) and receptor activation with adenosine triphosphate (ATP)
resulted in markedly enhanced IL-1 (a and b) secretion in BMDC compared with BMM. In both cell types
IL-1 production was profoundly inhibited with a P2X7R-speciﬁc inhibitor (A-740003) demonstrating that
this release is predominantly a P2X7R-dependent process. These data also suggest that P2X7R and
caspase-1 activation drive IL-1a release from BMDC. Both cell types expressed constitutively the
gain-of-function P2X7K as well as the full P2X7A variant at equivalent levels. LPS priming reduced signif-
icantly levels of P2X7A but not P2X7K transcripts in both BMDC and BMM. P2X7R-induced pore formation,
assessed by YO-PRO-1 dye uptake, was greater in BMDC, and these cells were protected from cell death.
These data demonstrate that DC and macrophages display distinct patterns of cytokine regulation, par-
ticularly with respect to IL-1, as a consequence of cell-type speciﬁc differences in the physicochemical
properties of the P2X7R. Understanding the cell-speciﬁc regulation of these cytokines is essential for
manipulating such responses in health and disease.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The interleukin (IL)-1 cytokines are among the most potent ini-
tiators of inﬂammation and are involved in a wide variety of protec-
tive host responses against viral, fungal, parasitic and bacterial
infections, but also contribute to damaging inﬂammatory processesin autoimmune inﬂammatory diseases including rheumatoid arthri-
tis and type-2 diabetes [1,2]. The IL-1 family consists of pro- and
anti-inﬂammatory molecules including the 3 main ligands IL-1b,
IL-1a and IL-18, the natural inhibitor of IL-1a and b IL-1 receptor
antagonist, the membrane-associated and decoy receptors (IL-1RI
and IL-1RII, respectively) and various accessory proteins [3,4].
IL-1a and IL-1b are the main pro-inﬂammatory forms, and are
known to initiate the synthesis of cyclooxygenase type 2, type-2
phospholipase A and inducible nitric oxide synthase, contributing
to the induction of fever, vasodilation and hypotension [5].
Although most cellular responses are shared between IL-1a and b
isoforms, both of which signal through the same receptor, impor-
tantly IL-1a is primarily cell associated, whereas IL-1b is secreted
[6]. There are also reports of isoform-speciﬁc functions, including
for example, the selective recruitment of neutrophils and macro-
phages being initiated by IL-1a and IL-1b, respectively [7].
The production of IL-1b is regulated at several checkpoints,
including transcription, translation, maturation and secretion, in
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b expression is regulated by pattern recognition receptors (PRR)
which are expressed by the immune sentinel cells that are the pri-
mary source of this cytokine (monocytes, macrophages and den-
dritic cells [DC]) that are specialized to recognize bacterial or
viral components. A major class of PRR and one that is often
manipulated experimentally are members of the Toll-like receptor
(TLR) family. Upon ligation of these receptors, inactive precursor
IL-1 molecules accumulate beneath the inner leaﬂet of the cell
membrane (reviewed in [9]). IL-1a and b precursors (pro-forms)
remain cytosolic until the ‘primed’ cell encounters an additional
stimulus. In order for processing and secretion of active IL-1
cytosolic PRR are activated. These typically belong to a family of
nucleotide-binding domain leucine-rich repeat containing recep-
tors, consisting of 23 members that are activated by pathogen or
damage associated molecular patterns (PAMPs or DAMPs respec-
tively), and form multi-molecular complexes known as inﬂamma-
somes [10]. Inﬂammasomes facilitate activation of the protease
caspase-1 that cleaves pro-IL-1b into an active form which is
required for the efﬁcient and rapid release of the cytokine into
the extracellular space [11,12]. Although not a substrate for
caspase-1, activation of the inﬂammasome also induces the pro-
cessing and release of IL-1a [13].
Extracellular adenosine triphosphate (ATP) represents a physio-
logical DAMP that induces rapid inﬂammasome and caspase-1
activation [14]. ATP is produced ubiquitously, is present in the
cytoplasm of every cell, is hydrophilic, and its extracellular concen-
tration is tightly regulated by ecto-ATPases, making it an ideal dan-
ger signal for potentiating immune responses [15]. The traditional
view, derived mainly from studies of macrophage populations, is
that ATP binds to P2X7R, triggering K+ efﬂux and activating
inﬂammasome-mediated IL-1b responses [16–18]. Recently, how-
ever, it has been shown that DC may also be potential sources of
P2X7R induced IL-1b and thus also contribute to IL-1-dependent
inﬂammatory responses [19]. Thus, the main objective of the pre-
sent investigation was to examine the role of the ATP-P2X7R axis in
mediating inﬂammasome activation and IL-1 release by DC and to
compare these responses with macrophages matured from the
same initial precursor cell preparations.
Activation of the P2X7R is associated with a wide variety of
functions beyond that of inﬂammasome activation and IL-1b
release [20], raising the question of whether a single receptor can
regulate such multiple actions. Recently, differential expression
of splice variants has been shown to signiﬁcantly alter the proper-
ties of the P2X7R functional trimer and has therefore been pro-
posed as an endogenous regulatory mechanism [21,22]. The
currently available anti-murine P2X7R antibodies do not discrimi-
nate between various splice variants. We have therefore examined
the expression of the ﬁrst reported variant (P2X7A) and a
gain-of-function isoform (P2X7K) at the transcriptional level in
murine bone marrow (BM) derived DC and BM macrophages
(BMM). Additionally, on the basis that localization and stabiliza-
tion of the P2X7R on the cell surface membrane, at least in micro-
glia and macrophages, is tightly regulated by a speciﬁc sequence
within a lipopolysaccharide (LPS)-binding motif [23], the effect of
LPS priming on the expression of various splice variant isoforms
of the receptor was investigated.2. Materials and methods
2.1. Experimental animals
Young (6–8 weeks old) female BALB/c strain mice (obtained
from Harlan Olac, Bicester, UK) were used. Mice were providedwith environmental stimuli (bedding and nesting material); food
(Beekay Rat and Mouse Diet No1 pellets; B&K Universal, Hull,
UK) and water were available ad libitum and environmental condi-
tions comprised a 12 h dark/light cycle at 21 C ± 1 C and
55% ± 10% humidity. Maintenance and treatment of animals were
conducted as speciﬁed by the U.K. Animals (Scientiﬁc
Procedures) Act 1986. Mice were sacriﬁced by exposure to a rising
concentration of C02 gas followed by dislocation of the neck in con-
cordance with schedule 1 (Animals [Scientiﬁc Procedures] Act
1986).2.2. Generation and culture of BMDC and BMM from BM progenitors
BM progenitor cells were isolated and cultured as described
previously [24]. BMDC (2  106 per 10 ml) were cultured in
RPMI-1640 medium containing 25 mM HEPES, 400 lg/ml peni-
cillin/streptomycin, 292 lg/ml L-glutamine, 0.1% (v/v)
2-mercaptoethanol and 10% (v/v) heat inactivated fetal calf serum
(FCS) (RPMI-10% FCS; all supplied by Invitrogen, California, USA)
containing 20 ng/ml granulocyte/macrophage-colony stimulating
factor (GM-CSF) (Peprotech, New Jersey, USA). BMM were cultured
under the same conditions, except DMEMmedium (Sigma–Aldrich,
Poole, Dorset, UK) was supplemented with 30% L-929 conditioned
medium in place of GM-CSF. Medium was refreshed every 3 days,
and cells were harvested on day 8 by gentle agitation (BMDC) or
following treatment with ethylene diamine tetraacetic acid
(EDTA) (0.25%, Sigma–Aldrich) (BMM). Viable cell counts were per-
formed by trypan blue exclusion and cells were seeded into
24-well tissue culture plates at 1  106 cells per well.
Cells prepared as described above were cultured in the presence
of various reagents: LPS (Escherichia coli serotype 055:B5; Sigma–
Aldrich), ATP (stored at 20 C as stock solution prepared at
100 mM and pH adjusted to 7.5; Sigma–Aldrich), the P2X7R inhibi-
tor A-740003 (Tocris Bioscience, Bristol, UK; dissolved in 0.5%
dimethyl sulfoxide [DMSO]), or apyrase (Sigma–Aldrich). Cells were
cultured with 1 or 1000 ng/ml LPS for 2 h, for the last 30 min of the
incubation in the presence of 0–10 mM ATP or 2–20 lg/ml of apyr-
ase. Cells that were treated with the P2X7R inhibitor A-740003
received various concentrations (0.1–100 lM) in DMSO or DMSO
alone for 10 min prior to the addition of ATP. At the end of every ser-
ies of treatments, supernatants were collected and the remaining
cell pellets were lyzed with 100 ll/well of lysis buffer (20 mM
Tris–HCl, 137 mM NaCl, 20 mM EDTA, 10% glycerol, 0.5% Ipegal,
phenylmethylsulfonyl [1 mM] and protease inhibitor cocktail
[1:100] (Calbiochem, San Diego, USA)) and lysates collected.
2.3. Cell viability assessment
The viability of cell populations after treatment with LPS or ATP
was assessed by propidium iodide (PI, 10 lg/ml; Sigma–Aldrich)
exclusion and analysis by ﬂow cytometry or by trypan blue exclu-
sion and analysis by light microscopy. In some experiments, viabil-
ity was assessed using lactate dehydrogenase (LDH) activity in
cultured, cell-free supernatants using the cytotoxicity detection
kit (ROCHE; Basel, Switzerland) according to the manufacturer’s
instructions. The LDH enzyme is stably expressed in most cells
and it is rapidly released when the plasma membrane is perturbed.
Therefore, an increase in LDH activity in cultured supernatants cor-
relates to an increase in the number of dying/dead cells in culture.
Cell viability was determined using an equation that compared the
LDH levels detected in the sample of interest to those obtained
from a ‘‘positive control’’ (cell-free supernatants collected from
freeze–thawed cells of the same type, BMDC or BMM and of equal
number) and a ‘‘negative control’’ (cell-free culture medium).
% cytotoxicity ¼ ðLDH activity in sample of interest LDH activity in negative controlÞðLDH activity in positive control LDH activity in negative controlÞ
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Cells (2  105) were stained with antibodies directed against
major histocompatibility complex (MHC) class II (clone 2G9, rat
IgG2a; 2.5 lg/ml), phycoerythrin (PE)-labelled hamster
anti-mouse CD11c (IgG1j; 4 lg/ml), PE-labelled anti-mouse
CD11b (rat IgG2a; 10 lg/ml), or isotype controls (rat IgG2a, rat
IgG2b or PE-labelled hamster IgG1j; all from BD Biosciences,
Princeton, New Jersey, USA), or with PE-labelled anti-mouse
F4/80 (rat IgG2a; 4 lg/ml; E Biosciences, Hatﬁeld, UK). For unla-
belled primary antibodies, cells were stained subsequently with
goat anti-rat IgG ﬂuorescein isothiocyanate (FITC)-labelled poly-
clonal antibody (7 lg/ml; AbD Serotec, Kidlington, Oxford, UK).
Incubations and washes were performed in 5% FCS in phosphate
buffered saline (PBS) at 4 C. Cells were re-suspended in sodium
azide buffer (0.05% sodium azide and 1% FCS). A FACScalibur
machine and CellQuest Pro software (BD Biosciences) were used
to analyze 104 cells and PI was used to exclude dead cells from
analysis and matching isotype control staining was used to set
gates. Data were expressed as % positive cells and as mean ﬂuores-
cence intensity (MFI).2.5. Western blot analysis of P2X7R and IL-1b expression
Cell lysates were prepared from cultured BMDC (1  106),
BMM or HEK-293 cells, and from freshly isolated peritoneal
macrophages (PM) (adherent peritoneal exudate population) or
splenocytes (prepared by mechanical disaggregation and ammo-
nium chloride lysis). Supernatants and lysates were diluted in
sample buffer (BioRad) containing 1% 2-mercaptoethanol and
heated at 80 C for 5 min. Protein concentration was determined
by modiﬁed Lowry (Bio-Rad, Berkeley, California, USA), and sam-
ples (20 lg protein) were resolved on a 10% sodium dodecyl sul-
fate polyacrylamide gel. The primary antibodies were rabbit
anti-mouse P2X7R (Alomone, Jerusalem, Israel; 3 lg/ml), or goat
anti-mouse IL-1b antibody (R&D Systems; Abingdon, UK;
0.1 lg/m) and the secondary antibodies were horse radish
peroxidase-conjugated goat anti-rabbit IgG (AbD Serotec) or horse
radish peroxidase-conjugated rabbit anti-goat IgG antibody
(DAKO, Copenhagen, Denmark): 50 ng/ml or 0.25 lg/ml, respec-
tively. A Super Signal West Pico chemiluminescent substrate
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts, USA) was
used to visualize protein expression using hyperﬁlm (Amersham
Biosciences/GE Healthcare, Little Chalfont, Buckinghamshire, UK)
and a medical ﬁlm processor (Xograph Imaging System, Compact).2.6. Electrophysiological recordings
BMDC were stained with PE-labelled anti-CD11c antibody and
individual positive cells were voltage-clamped to measure ion cur-
rents following P2X7R activation. Recording pipettes were pre-
pared from borosilicate glass (Harvard Apparatus, Kent, UK) with
resistances of 2–5 MX. The intracellular pipette solution con-
tained: 147 mM NaCl, 10 mM HEPES and 10 mM EGTA. The extra-
cellular recording solution contained 147 mM NaCl, 10 mM HEPES,
13 mM glucose, 2 mM KCl, 2 mM CaCl2 and 1 mM MgCl2. All solu-
tions were maintained at 300–320 mOsm/L and pH 7.3 (adjusted
with NaOH). Whole-cell patch clamp recordings were made at
room temperature using a HEKA EPC9 patch clamp ampliﬁer and
Pulse acquisition software (HEKA Elektronik GmbH, Lambrecht,Germany) at a holding potential of 60 mV. The data were
low-pass ﬁltered at 3 kHz and sampled at 1 kHz. ATP and
A-740003 were applied using an RSC-160 rapid perfusion system
(BioLogic, Claix, France), with oriﬁces positioned approximately
100 nm away from the cell under investigation.
2.7. YO-PRO-1 dye uptake assay
Concurrent cultures of day 8 BMDC or BMM were transferred
into 96-well tissue culture plates (black with clear bottom) at
3  105 cells per 0.2 ml and incubated overnight at 37 C and 5%
CO2 and allowed to adhere. Cells were either untreated or primed
with 1000 ng/ml of LPS for 2 h and washed with PBS before the
addition of 100 ll/well of YO-PRO-1 (10 lM; Tocris Bioscience)
solution, prepared in standard extracellular solution (136 mM
NaCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.8 mM KCl, 1.2 mM CaCl2,
5 mM NaHCO3, 20 mM HEPES and 5.5 mM of glucose).
Fluorescence (495 nm/515 nm excitation/emission) was moni-
tored using a ﬂuorescent laser imaging plate reader (Flex Station
3; Molecular Devices, San Francisco, USA). After recording a base-
line current ﬂow for a 30 s interval, ATP at 1 or 5 mM was applied
to LPS primed or unprimed cells. YO-PRO-1 ﬂuorescence was mea-
sured at 3 s intervals throughout the procedure and a mean ﬂuo-
rescence value was obtained for triplicate wells.
2.8. Cytokine enzyme-linked immunosorbant assay (ELISA)
Lysate (intracellular) and supernatant (secreted) IL-1a and
IL-1b levels were determined using DuoSet ELISA kits (R&D sys-
tems) according to the manufacturer’s instructions. The DuoSet
antibodies did not differentiate between precursor and mature
forms of IL-1. IL-6 content was measured using a speciﬁc mouse
sandwich ELISA (as described in [25]). The lower limits of accurate
detection for IL-1 and IL-6 were approximately 40 and 80 pg/ml,
respectively.
2.9. Analysis of P2X7R splice isoform expression by quantitative-
polymerase chain reaction (q-PCR)
Total RNA was extracted from the cell populations of interest
using an RNA isolation system (TRIzol RNA minikit, Invitrogen)
according to the manufacturer’s instructions and subsequently
treated with DNase (Ambion, Life Technologies, Carlsbad,
California, USA). An equal amount of RNA (300 ng) was reverse
transcribed using a high capacity RNA-to-cDNA kit (Invitrogen). A
dye based (SYBR Green) qPCR was used to obtain relative quantiﬁ-
cation of mRNA levels of the various P2X7R isoforms of interest rel-
ative to the housekeeping gene hypoxanthine–guanine
phosphoribosyltransferase (HRPT). (HPRT: forward: GGG CTT ACC
TCA CTG CTT TC, reverse: TCT CCA CCA ATA ACT TTT ATG TCC;
P2X7A: forward: CAC ATG ATC GTC TTT TCC TAC, reverse: GGT
CAG AAG AGC ACT GTG C; P2X7K: forward: GCC CGT GAG CCA
CTT ATG C reverse: GGT CAG AAG AGC ACT GTG C. All primers were
obtained from Sigma–Aldrich and were checked against GenBank
for selectivity. A melt curve was also performed for all primers to
ensure that they recognized and ampliﬁed a single product. qPCR
reactions were performed using a SensiFAST no-ROX Kit (Life
Technologies) according to the manufacturer’s instructions. All
samples were run in triplicate in an ABI StepOnePlus PCR machine
(Applied Biosystems, Life Technologies) using the following
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(denaturation), 60–65 C for 10 s (annealing) and 72 C for 5–20 s
(elongation). Samples were considered positive if the ampliﬁcation
curve crossed the set threshold (set automatically). Fold changes in
gene expression for each P2X7R splice isoform were normalized to
the housekeeping gene (HPRT) and calculated using the 2DDCT
method. PCR samples along with a 100 bp interval ladder
(BIOLINE, London, UK) were separated on a 1% agarose gel with
ethidium bromide dissolved in TBE buffer (Promega). The bands
were visualized using a UV-transluminator (Syngene, Cambridge,
UK) and photographed using a polaroid camera.2.10. Data analyses
Data were analyzed using Prism 6.0 and multiple comparisons
were considered using one-way ANOVA. A two-tailed Student’s
t-test was employed for comparisons between two different
groups. Dunnett’s multiple comparison post-hoc test was
employed for comparisons with a control group. Tukey’s test was
employed when comparisons were made between all treatment
groups and two-way ANOVA and Sidak’s multiple comparison
post-hoc tests were employed for comparisons between differentFig. 1. Phenotypic characterization of murine BMDC and BMM. BMDC (h) and BMM (j)
surface of expression of MHC class II, CD86 (data not shown), F4/80, CD11b and CD11c. D
the isotype controls, and with respect to (b) the percentage of positive cells and (c) MFI
The statistical signiﬁcance of differences between BMDC and BMM was assessed by onetreatments of two cell types of interest. Signiﬁcant differences
are illustrated by ⁄p < 0.05.3. Results
3.1. Phenotypic differences between BMDC and BMM
Membrane marker protein expression of day 8 BMDC and BMM
isolated in parallel from the same progenitor cells was character-
ized by ﬂow cytometry (Fig. 1). Consistent with previous reports
[24] the majority of BMDC displayed a DC phenotype expressing
relatively high levels of MHC class II and the DC associated marker
CD11c, but low levels of the macrophage marker F4/80
(Fig. 1b and c). In contrast, BMM exhibited a typical macrophage
proﬁle with high levels of F4/80 and low levels of both MHC class
II and CD11c (Fig. 1b and c). Both cell types (90%) displayed sim-
ilar levels of CD11b, an integrin found on macrophages and some
DC populations (Fig. 1). These BMDC and BMM cell populations
were analyzed for P2X7R expression at the level of transcription
(by qPCR, data not shown) and protein (by Western blotting), the
latter using a polyclonal rabbit antibody with speciﬁcity for a
P2X7R intracellular terminus epitope (Fig. 2a). Cell lysates werewere harvested after 8 days of culture and 104 cells analyzed by ﬂow cytometry for
ata are shown as (a) representative histograms, where closed histograms represent
(arbitrary units) and are displayed as mean ± SEM (n = 3 independent experiments).
-way ANOVA and Dunnett’s multiple comparison post hoc test (⁄ = p < 0.05).
Fig. 2. CD11c+ murine BMDC display functional P2X7R. Cell lysates were collected
from 106 day 8 BMDC or BMM or HEK-293 cells (negative control), or from an
equivalent number of freshly isolated splenocytes or PM. Parallel aliquots of cells
were lyzed and equivalent amounts of protein (20 lg) from each cell type were
analyzed for P2X7R expression byWestern blotting. Representative images from the
same analysis are shown. A total of three independent preparations were analyzed
(data not shown). Images were cropped and reordered (a). mRNA expression of
P2X7R was also evaluated for each cell population using qPCR. The same pattern
was detected at the level of message (data not shown). Day 8 BMDC at 0.25  106/
ml were cultured on glass coverslips and stained with anti-CD11c antibody to
identify CD11c+ cells before individual cells were patch clamped. Representative
traces showing current facilitation in clamped CD11c+ BMDC following repeated
applications of ATP at 5 mM (for 30 s at 30 s intervals) are shown (b). ATP was
applied at 61 mM, 3 mM and 5 mM to fully facilitated CD11c+ BMDC channels
(representative traces from n = 6 experiments) (c). Responses to 5 mM ATP were
measured in the presence and absence of the speciﬁc P2X7R inhibitor, A-740003
(0.1 mM). A-740003 was applied for 20 s during a sustained application of ATP
(5 mM, 30 s), as shown. An ATP control recording (30 s) was made 30 s before the
addition of A-740003 (representative traces from n = 6 experiments are shown) (d).
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unfractionated splenocytes. Negative control lysates were obtained
from cultured HEK-293 cells that do not express P2X7R. qPCR and
Western blotting, respectively, revealed the presence of P2X7A
mRNA (data not shown) and protein at the appropriate molecular
weight (75 kDa) in all cell types apart from the HEK-293 lysates
(Fig. 2a).
3.2. Murine CD11c+ BMDC express a functional P2X7R receptor
Although P2X7R expression in BMDC lysates was shown using
Western blotting, given that 30% of the BMDC population did
not express CD11c, it was necessary to demonstrate at the single
cell level CD11c positivity and P2X7R functionality, measured elec-
trophysiologically by patch clamping. Day 8 BMDC were stained
for CD11c expression and individual CD11c+ cells were
voltage-clamped in situ. Current facilitation (increase in current
amplitude in response to consecutive agonist applications) is a
characteristic property of the P2X7R [26] and is consistent with
the ﬁndings that the amplitude of inward BMDC current increased
2-fold during each of three consecutive applications of ATP
(Fig. 2b; representative traces for 5 mM ATP at 30 s intervals).
Whole-cell currents recorded during application of ATP (0.1–
5 mM, 20 s) revealed dose dependent responses (Fig. 2c; represen-
tative traces). Inward currents of 3.2 ± 0.7 and 6.1 ± 1.0 pA/pF
(n = 7) were observed in response to 3 and 5 mM ATP, respectively,
whereas 61 mM ATP failed to elicit a detectable current. The effect
of the speciﬁc P2X7R inhibitor, A-740003, on ATP-evoked currents
in BMDC was also investigated (Fig. 2d; representative traces).A-740003 (0.1 mM, 20 s) was co-applied with ATP (5 mM, 30 s),
and signiﬁcantly inhibited currents evoked by ATP alone by
93 ± 2% (n = 6; p < 0.05).
3.3. Different P2X7R-induced IL-1 cytokine responses in BMDC and
BMM
Subsequently the ability of LPS and ATP to induce IL-1 expres-
sion and release by BMDC and BMM was examined. Cells were
primed with low (1 ng/ml) or high (1000 ng/ml) dose LPS for
90 min followed by a 30 min incubation with ATP (0.5–10 mM).
IL-1b levels were quantiﬁed in both lysates (i.e. intracellular con-
tent) (Fig. 3a and b) and supernatants (reﬂecting cytokine release)
(Fig. 3c and d). There was no detectable cytokine expression fol-
lowing culture with medium or ATP alone at any concentration
with either cell type (data not shown). BMM were more sensitive
to LPS priming than were BMDC, at least with respect to intracel-
lular cytokine production. At the lower LPS dose (1 ng/ml), there
was little IL-1b detected in either lysates or supernatant following
treatment of BMDC whereas BMM were primed successfully with
approximately 4 ng/ml of cytokine detected in the lysate.
However, challenge with ATP did not provoke detectable secretion,
instead concentrations of 5 mM ATP and above resulted in
decreased intracellular cytokine content. For both cell types there
was signiﬁcant priming with high dose LPS, with approximately
20 ng/ml IL-1b recorded in lysates following incubation with LPS
alone. Here BMDC were more responsive than BMM with respect
to both maximal amounts of secreted product (16 ng/ml versus
2 ng/ml) and the minimum amount of ATP that induced signiﬁcant
secretion (1 versus 5 mM). Furthermore, BMDC tolerated the high
dose of ATP, with maximal secretion still recorded after challenge
with 10 mM ATP, whereas BMM were unable to secrete IL-1b
under the same conditions. For both cell types, ATP-induced cyto-
kine secretion was associated with a concomitant drop in intracel-
lular IL-1b levels. In order to exclude the possibility that IL-1b
release was simply due to ATP-induced cytotoxicity, following
detachment of both cell populations with EDTA, viability was
assessed by PI staining (Fig. 3e and f). ATP treatment did not signif-
icantly affect BMM viability, whereas for BMDC there was a
marked reduction (from 95% to 50%) in viability only when cells
were primed with 1000 ng/ml LPS and challenged with 5 mM
ATP. Interestingly, incubation with 10 mM ATP did not affect cell
viability.
Given the marked reduction in viability (assessed by PI exclu-
sion) recorded for BMDC challenged with 5 mM ATP, alternative
measures of viability were explored. Release of LDH was an appro-
priate endpoint for the measurement of BMM viability, with LDH
assay results paralleling those obtained with PI exclusion (no
marked effect of ATP)(data no shown). However, this endpoint
was not of utility for the measurement of BMDC viability.
Although there was apparently little impact of treatment with
either LPS or ATP on the viability of BMDC compared with
medium-treated controls with respect to LDH release, the baseline
viability of untreated BMDC was apparently very low (20%
viable). Therefore BMDC viability was assessed using trypan blue
exclusion (Fig. 4a). These data demonstrated that although there
was a small drop in viability following LPS treatment, the addition
of ATP in the concentration range utilized herein (0.5–10 mM) was
without signiﬁcant effect on cell viability. The same pattern of
IL-1b expression was recorded as that observed previously:
LPS-stimulated BMDC expressed intracellular cytokine and ATP
challenge was necessary for the secretion of IL-1b (Fig. 4b).
Furthermore, Western blot analysis of lysates and supernatants
conﬁrmed that intracellular IL-1b detected in LPS primed cells
was all in the precursor, pro-IL-1b form (Fig. 4c; representative
blot). Non-speciﬁc binding was also evident in the analysis of
Fig. 3. Differential IL-1b production and secretion by BMDC and BMM following LPS priming and ATP activation. Day 8 BMDC (h) and BMM (j) at 106/ml were cultured for
2 h with 1 (a, c, e) or 1000 ng/ml (b, d, f) LPS then challenged for the last 30 min with ATP at 0, 0.5, 1, 5 or 10 mM. Negative control cells were cultured with medium alone
throughout (med). Intracellular (a, b) and secreted (c, d) levels of IL-1b were quantiﬁed by cytokine-speciﬁc ELISA. Cells were stained with PI and cell viability of BMDC (h)
and BMM (j) was assessed by ﬂow cytometry (e, f). Data shown are mean ± SEM (n = 3 independent experiments). Statistical signiﬁcance of differences within BMDC/BMM
populations between medium- and LPS alone-treated cells was considered by a two-tailed Student’s t-test (§ = p < 0.05) and between the LPS-treated groups (LPS alone-
treated cells were used as the comparator) was assessed by one way ANOVA and Dunnett’s multiple comparison post-hoc test (⁄ = p < 0.05).
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non-speciﬁc band without bands at the right size for mature or
pro-IL-1beta was also detected when medium/FCS alone was ana-
lyzed (data not shown). Upon stimulation of LPS-primed cells with
5 mM or 10 mM ATP, IL-1bwas detected in both lysates and super-
natants. The cytokine in the lysates was the precursor (31 kDa)
form whereas in the supernatants it was primarily in the mature,
17 kDa processed form.
IL-1a production and release was also monitored for the same
experimental protocol (Fig. 5a and c). The pattern of IL-1b and
IL-1a production was similar as were the dose response proﬁles.
Thus, high dose LPS primed BMDC for IL-1a production (intracellu-
lar expression) but signiﬁcant secretion was only observed follow-
ing challenge with ATP, and this was paralleled by a reduction in
cytokine content of lysates. BMM were considerably less effective
at producing this cytokine (2 versus 9 ng/ml in lysates and <0.2
versus 6 ng/ml in supernatants). Expression of IL-6, a
pro-inﬂammatory cytokine that does not share the same
inﬂammasome-associated pathway of secretion as the IL-1 family,
was also investigated (Fig. 5b and d). Only LPS-primed BMDC were
able to elaborate IL-6, which was secreted without any require-
ment for ATP challenge.
The P2X7R speciﬁc inhibitor A-740003 was employed to vali-
date the role of P2X7R signalling in LPS/ATP-induced IL-1 produc-
tion by BMDC and BMM under conditions optimal for IL-1
release (priming with 1000 ng/ml LPS and challenge with 5 mM
ATP; Fig. 6). As described above (cf. Figs. 3 and 5), LPS priming ofBMDC resulted in signiﬁcant up-regulation of both isoforms of
IL-1, but was unable to cause secretion. Treatment with ATP
resulted in secretion (15 ng/ml) and a concomitant drop in intra-
cellular cytokine levels, which was blocked almost completely
(>95% inhibition) by the addition of 0.1 mM A-740003. The inhibi-
tory effects on IL-1b production by BMM were similar, with effec-
tive blocking with A-740003 (91%), although ATP-induced
secretion was less robust (1 ng/ml), and BMM were ineffective
at upregulating IL-1a production. With regards to IL-6 expression
(data not shown), activation with exogenous ATP (5 mM) had no
signiﬁcant effect on IL-6 release and, importantly, neither did
treatment with A-740003. Also consistent with previous experi-
ments, treatment of BMM with ATP was without signiﬁcant toxic-
ity (viability varied between 90% and 80% regardless of treatment),
whereas BMDC displayed a reduction in cell viability as measured
by PI exclusion upon ATP treatment (from 95% to 60%) which was
reversed by incubation with the P2X7R inhibitor.
In order to exclude a role for adenosine diphosphate or
monophosphate signalling in mediating IL-1 secretion from
LPS-primed BMDC, the ATP-degrading enzyme, apyrase, was
employed [27]. LPS-primed BMDC were treated with apyrase
immediately prior (30 s) to challenge with 1 mM ATP and IL-1a
and b production assessed (Fig. 6e and f). Apyrase was without sig-
niﬁcant effect on cell viability (data not shown) or intracellular
cytokine content, but caused a dose dependent inhibition of secre-
tion of both cytokines, with signiﬁcant inhibition (>90%) recorded
at 20 lg/ml. However, apyrase did not impact on the more
Fig. 4. BMDC secrete mature IL-1b following LPS priming and ATP. Day 8 BMDC at 106/ml were cultured for 2 h with 1000 ng/ml LPS then challenged for the last 30 min with
ATP at 0, 0.5, 1, 5 or 10 mM. Negative control cells were cultured with medium alone throughout (med). Viability was assessed by trypan exclusion (a) and intracellular and
secreted levels of IL-1bwere quantiﬁed by cytokine-speciﬁc ELISA (b). Data shown are mean ± SEM (n = 2 for 0.5 and 1 mM ATP with regards to cytokine analysis and n = 3 for
all other groups, independent experiments). Statistical signiﬁcance between medium- and LPS alone-treated cells was considered by a two-tailed Student’s t-test
(§ = p < 0.05) and between the LPS-treated groups (LPS alone-treated cells were used as the comparator) was assessed by one way ANOVA and Dunnett’s multiple comparison
post-hoc test (⁄ = p < 0.05). Parallel aliquots of cells were lyzed and equivalent amounts of lysate protein (20 lg) and supernatants were analyzed for IL-1b expression by
Western blotting. Representative images from the same analysis are shown. A total of three independent preparations were analyzed (data not shown). Images were cropped
(c). The band at 25 kDa that is present in all supernatant samples represents non-speciﬁc binding to elements in the FCS. A protein marker lane on each gel was used to
determine molecular weights of bands.
Fig. 5. BMDC and BMM IL-1a and IL-6 responses following LPS priming and ATP challenge. Day 8 BMDC (h) and BMM (j) at 106/ml were cultured for 2 h in the presence of
medium alone (med) or LPS (1000 ng/ml) and challenged for the last 30 min with ATP at 0, 0.5, 1, 5 and 10 mM. Both intracellular (a, b) and secreted (c, d) levels of IL-1a (a, c)
and IL-6 (b, d) were quantiﬁed by cytokine-speciﬁc ELISA. Data shown are mean ± SEM (n = 3 independent experiments). Statistical signiﬁcance of differences within BMDC/
BMM populations between medium- and LPS alone-treated cells was considered by a two-tailed Student’s t-test (§ = p < 0.05) and between the LPS-treated groups (LPS alone-
treated cells were used as the comparator) was assessed by one way ANOVA and Dunnett’s multiple comparison post-hoc test (⁄ = p < 0.05).
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Fig. 6. Impact of P2X7R inhibition or apyrase treatment on IL-1b expression by BMDC and BMM. BMDC and BMM at 106/ml were cultured for 2 h in the presence of LPS
(1000 ng/ml). Approximately 30 min before the end of culture, cells were treated with DMSO (0.5%) or with A-740003 (0.1 mM) formulated in DMSO (a–d). For the ﬁnal
20 min of culture, selected wells were challenged with 5 mM of ATP or were untreated. Negative control cells were cultured in the presence of medium alone throughout
(med). Alternatively, LPS-activated BMDC were treated with medium or apyrase (2, 20 lg/ml) immediately (30 s) before they were challenged with ATP at 1 mM for the ﬁnal
20 min of culture (e, f). Intracellular (a, c, e) and secreted (b, d, f) levels of IL-1b (a, b, e (j), f (j)) and IL-1a (c, d, e, (h), f (h)) were quantiﬁed by cytokine-speciﬁc ELISA. Data
shown are mean ± SEM (n = 3 independent experiments). Statistical signiﬁcance of differences within BMDC/BMM populations (a–d) between medium- and LPS alone-treated
cells (§ = p < 0.05), between LPS-primed and LPS-primed/ATP challenged cells (R = p < 0.05) and between LPS-primed/ATP-challenged cells treated with DMSO or with A-
740003 (⁄ = p < 0.05) were considered by paired two-tailed Student’s t-test. For apyrase experiments (e, f) for each cytokine the statistical signiﬁcance of differences between
medium- and LPS alone-treated cells (§ = p < 0.05), LPS-primed and LPS-primed/ATP challenged cells (R = p < 0.05) and between LPS-primed/ATP-challenged cells treated
with medium or apyrase/A-740003 (⁄ = p < 0.05) were considered by paired two-tailed Student’s t-test.
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and it was not possible to use higher concentrations of enzyme as
these were cytotoxic (data not shown).
3.4. P2X7R splice variant proﬁles are similar for BMDC and BMM
The role of expression of distinct P2X7R splice variants in the
differential responses of BMDC and BMM was investigated using
qPCR (Fig. 7a and b). Levels of transcripts of the different receptor
isoforms were normalized to expression in unfractionated freshly
isolated splenocytes. Both cell types displayed similar baseline
levels of P2X7K mRNA to those found in splenocytes, but expressed
some 100-fold and 1000-fold higher levels of P2X7A, respectively.
LPS activation was without impact on P2X7K transcripts, whereas
expression of P2X7A was markedly down-regulated (approxi-
mately 10-fold) on both cell types and to similar extents.3.5. Differential pore formation characteristics of the receptor in BMDC
and BMM
Another characteristic property of the P2X7R is progressive pore
dilation during sustained receptor activation [28]. This dilation
increases the permeability of the receptor to large ﬂuorescent dyes
such as YO-PRO-1, leading to extracellular dye uptake. BMDC
P2X7R dilation was compared with that of the well-characterized
BMM P2X7R using a YO-PRO-1 uptake assay developed on the
Flexstation-3 ﬂuorescent plate reader (Fig. 7c and d). At ﬁrst, lower
concentrations (1lM) of YO-PRO-1 were investigated, but such did
not achieve sufﬁcient sensitivity for analysis. At higher concentra-
tions (10lM) of YO-PRO-1, both BMDC (Fig. 7c) and BMM (Fig. 7d)
were seen to accumulate YO-PRO-1 in response to ATP (1 mM,
90 min), measured as a function of a time-dependent increase in
ﬂuorescence; no uptake was observed in the absence of ATP. LPS
Fig. 7. P2X7R-induced pore formation and splice variant expression proﬁles in BMDC and BMM. Cells (106/ml) were incubated in medium alone (med) or in the presence of
LPS (1000 ng/ml) for 2 h. mRNA expression levels for each splice variant were measured using qPCR. Levels of mRNA for (a) P2X7K and (b) P2X7A were normalized to the
expression levels of the housekeeping gene, HPRT, and are expressed as fold changes relative to expression levels detected in unfractionated splenocytes. Data are shown as
mean (±SEM) and three independent BMDC (h) and BMM (j) preparations. Statistical signiﬁcance of differences between groups within BMDC/BMM populations was
assessed with a paired two-tailed Student’s t-test (⁄ = p < 0.05). BMDC (c) and BMM (d) at 0.3  106/ml were incubated in medium alone or in the presence of 1000 ng/ml LPS
for 2 h and subsequently challenged with 1 mM ATP or with medium for up to 90 min (medium alone s; LPS alone, h; medium/ATP, d; LPS/ATP, j). Time-dependent YO-
PRO-1 dye uptake was recorded as changes in ﬂuorescence measured at 3 s intervals for 90 min, using a Flex Station 3. Traces are presented as relative ﬂuorescence units over
time. The same experimental setup was used to measure cumulative levels of dye uptake (relative ﬂuorescence units) for medium-treated (e) or LPS-treated (f) BMDC (open
columns) and BMM (closed columns) 85 min post challenge with 1 mM or 5 mM ATP. Data shown are mean ± SEM (n = 3 independent experiments). Statistical signiﬁcance of
differences within BMDC/BMM populations was considered between the various groups (using ATP-treated cells or LPS-treated cells as a comparator) at 85 min post ATP
activation and assessed by one way ANOVA and Dunnett’s multiple comparison post-hoc test (⁄ = p < 0.05).
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ably but was without effect on dye uptake by BMM. Additionally,
LPS alone was not sufﬁcient to elicit YO-PRO-1 uptake by either cell
type. This pattern of YO-PRO-1 uptake was conﬁrmed when the
cumulative levels of dye uptake were quantiﬁed in
medium-treated and LPS-primed BMDC and BMM in the presence
or absence of 1 mM ATP challenge (Fig. 7e and f). Interestingly,
however, challenge with 5 mM ATP abrogated the LPS priming
effect for BMDC whereas BMM displayed enhanced dye uptake in
the presence of 5 mM ATP regardless of LPS priming (Fig. 7f).4. Discussion
These investigations have focused on characterizing P2X7R
expression and functional activity, principally via the secretion ofIL-1, by murine BMDC in comparison with BMM. P2X7R expression
by both cell types was established by Western blot analysis and
qPCR. More precisely, Western blot analysis revealed expression
of a 75 kDa protein in BMDC and BMM suggesting the presence
of full-length wild type receptor (P2X7A) or gain-of-function vari-
ants such as the P2X7K. Although efforts were made to detect pro-
tein expression with an antibody directed against an epitope
situated in the extracellular loop of the protein thereby enable fur-
ther investigations expression of different variants at the protein
level, this proved unsuccessful (data not shown). The presence of
P2X7R splice variants was therefore addressed at the mRNA level
and is discussed below. Loss-of-function P2X7R variants have been
shown to lack most of the intracellular C-terminal tail and there-
fore their expression cannot be detected using the commonly used
antibody directed against epitopes of the C-terminal region.
Detection of their expression is only possible using antibodies
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however, they can be distinguished from the full-length variants
due to a difference in protein size (approximately 60 kDa), as
shown by Masin and colleagues [29]. Nevertheless, it is clear that
with the current tools available in murine tissue it is only possible
to distinguish at the protein level between full-length and
loss-of-function variants, such as the P2X7A and P2X713b but not
between the P2X7A and P2X7K. The idea that different splice vari-
ants help shape the function of the full-length P2X7A variants in
different cell types is beginning to emerge, which requires a more
collective effort to proﬁle the expression of the various splice vari-
ants in different mammalian tissues.
As BMDC preparations were 70% DC, CD11c+ cells were specif-
ically targeted by patch clamping for electrophysiology studies.
These experiments extend previous observations of P2X7R expres-
sion by DC populations and provide for the ﬁrst time functional
evidence of receptor expression in CD11c+ murine BMDC with
pharmacology similar to that of the recombinant murine receptor
expressed in HEK cells [30]. Differential patterns of IL-1 production
and secretion were recorded for the two cell types. BMM were
more sensitive with respect to the threshold concentration of LPS
necessary for priming, whereas BMDC were more effective at IL-1
secretion, which was more robust and was sustained across a
wider range of ATP concentrations. For both cell types LPS priming
resulted in intracellular IL-1 expression but challenge with ATP
was required for cytokine secretion.
Differential LPS-induced IL-1 production by DC and macro-
phages has been reported previously by He and colleagues [19].
BMDC were found to express higher levels of constitutive NLRP3
than macrophages, thereby providing for more rapid inﬂamma-
some activation and IL-1b processing. However, in those experi-
ments a combination of apyrase and P2X7R KO mice were used
to demonstrate that neither ATP nor P2X7R signalling were
required for LPS-induced (24 h treatment) cytokine release in mur-
ine BMDC [19]. Given that a single relatively low dose of apyrase
was also employed in those experiments, it could be argued that
such was insufﬁcient to ensure that the transient, successive waves
of ATP typical of the receptor activation were effectively degraded.
Furthermore, the recent identiﬁcation of functional splice variants
of P2X7R in P2X7R KO mice [22,29] suggests that such mice must
be used in conjunction with speciﬁc P2X7R inhibitors in order to
provide deﬁnitive information as to the relevance of the receptor.
In contrast, the investigations reported herein have employed the
potent and speciﬁc P2X7R inhibitor A-740003 [31] which was
shown to effectively block the release of IL-1b from both murine
BMDC and BMM. Indeed, this is the ﬁrst study to demonstrate inhi-
bition of IL-1b in murine BMDC using this drug. Given the reported
speciﬁcity of A-740003 for the P2X7R, these data provide indirect
but convincing evidence that a functional P2X7R is expressed on
both cell types and demonstrates the requirement of P2X7R sig-
nalling in IL-1b release from in vitro cultured DC and macrophages.
The receptor is also important for human immune cell function,
with studies in subjects with the loss-of-function Glu496Ala
P2X7R polymorphism revealing a requirement for a functional
P2X7R for effective IL-1b or IL-18 secretion by monocytes [32].
Further, the P2X7R and its role in IL-1b production has been shown
to be critical for the sensitization phase of contact hypersensitivity
[27].
The selective prozone effects of high dose ATP on BMM,
whereby intracellular IL-1b expression was down-regulated with-
out concomitant secretion, suggested that the intracellular cyto-
kine content is actively targeted for degradation. Both lysosomal
and proteosomal pathways have been shown to be involved in
the regulation of IL-1b bioavailability by facilitating the degrada-
tion of IL-1b molecules or individual inﬂammasome components
[33,34]. In addition, autophagy is apparently more strictlycontrolled in DC [35]. Suppression of autophagy and constitutive
expression of higher levels of inﬂammasome components [19]
could theoretically contribute to more vigorous IL-1b production
by DC. A differential capacity to regulate the bioavailability of
ATP and its metabolites may also play a role. For example, DC have
been shown to possess strong adenosine deaminase activity at the
cell surface to overcome the suppressive effects of adenosine
which accumulates as a result of ATP degradation and signals
through P1 receptors to counter-act pro-inﬂammatory processes
[36,37]. These processes provide mechanisms whereby DC are kept
in a state of readiness for initiating immune and inﬂammatory
responses whereas macrophages are maintained in a more quies-
cent state with little or no production of pro-inﬂammatory agents.
BMDC and BMM also displayed differential secretion of IL-1a
and IL-6 with relatively little production of these cytokines
recorded for BMM under any conditions. Classically IL-1a secretion
does not require inﬂammasome activation, despite being
up-regulated by the same TLR ligands that induce IL-1b production.
However, recent evidence suggests that IL-1amay also be released
via the classic inﬂammasome-dependent secretory pathway of
IL-1b [38–40]. In BMM, which exhibit an immunosuppressive pro-
ﬁle, both isoforms of IL-1 could be speciﬁcally targeted by
autophagosomes for destruction [35]. The general consensus is
that IL-1a is secreted via passive diffusion from necrotic DC follow-
ing injury [41]. However, consistent with the results of the study
reported herein, Fettelschoss and colleagues demonstrated
P2X7R-mediated IL-1a release by murine BMDC [40]. Thus,
LPS-primed/ATP-challenged BMDC derived from NLRP3 and
P2X7R KO mice failed to release IL-1a, as well as IL-1b.
Additionally, consistent with previous reports [42], murine
LPS-primed BMM failed to synthesize detectable levels of IL-6
highlighting further the divergent responses of DC and macro-
phages with respect to cytokine production induced by the same
bacterial ligands/danger signals. In BMDC, IL-6 expression and
release was driven by LPS-, not -ATP, signalling and was
P2X7R-independent.
In order to provide a possible mechanistic basis for the differen-
tial LPS- and ATP-driven cytokine responses by DC and macro-
phages transcriptional levels of two P2X7R functional splice
variants was examined. As such, this study represents the ﬁrst
demonstration of the expression of the gain-of-function P2X7K
transcripts by murine BMDC and BMM. However, the functional
differences observed between the two cell types could not be rec-
onciled on the basis of constitutive, or LPS-induced, differential
splice variant mRNA expression. It is possible that splice variant
expression modulates P2X7R function at the level of translation
and would not therefore be resolved using the current methods.
At present, the topic of splice variants and their relative contribu-
tion to P2X7R function in primary tissues is still in its infancy, but
once appropriate tools become available, analysis of the interac-
tions of the variant receptors with the various adaptor, anchor or
scaffolding proteins and the ability to form stable P2X7R trimers
on the cell surface membrane may show cell speciﬁc patterns.
The impact of ATP on BMDC viability was somewhat surprising.
Thus, challenge with 5 mM ATP induced a substantial drop in the
viability of LPS-primed BMDC (assessed as a function of PI staining)
whereas 10 mM ATP had little impact on cell viability. However,
assessment of viability using trypan blue exclusion as the end
point indicated that there was no signiﬁcant drop in viability in
the presence of 5 mM ATP. This is consistent with a recent study
demonstrating that organic dyes such PI could in theory enter
through the P2X7R channel itself which under sustained activation
with mM levels of ATP results in pore formation [43]. Thus, the
enhanced PI staining observed in BMDC could reﬂect an active
P2X7R channel that allows PI entry. At higher levels of ATP
(10 mM), it is assumed that BMDC have a mechanism in place to
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which would result in irreversible cell damage. The kinetics of pore
formation and the level of permeabilization in murine BMDC and
BMM were examined further. Although the density of receptor
expression was not examined, these YO-PRO-1 uptake assays pro-
vide information as to the functional properties of the receptor in
the two cell types [44]. Application of mM levels of ATP induced
pore formation and dye uptake in both unprimed and
LPS-primed BMDC and BMM, suggesting that dye uptake is an
ATP-mediated effect and the result of P2X7R activation. The pattern
of dye uptake by BMM was similar to that observed previously in a
murine microglial cell line [45]. The rate of dye uptake in
LPS-primed and ATP-challenged (1 mM) BMDC was faster and
the ﬂuorescence signal was greater than that observed in
LPS-primed BMM. Also of note was the fact that LPS-primed DC
and macrophages displayed opposing responses to increasing con-
centrations of ATP. Whereas in BMM the levels of dye uptake
increased markedly at higher concentrations of ATP, the converse
was observed with BMDC. Similar responses to BMDC were
reported recently for primary astrocyte cultures whereby
YO-PRO-1 dye uptake was reduced at higher concentrations of
ATP in a dose-dependent manner [46]. It is widely accepted that
prolonged ATP-induced pore formation results in the loss of cell
viability. Thus, DC, being frequently exposed to excessive levels
of ATP at sites of tissue injury are perhaps required to distinctly
regulate pore formation as a protective mechanism.
The molecular platform that forms the P2X7R pore and whether
this facilitates the release of IL-1 cytokines remains elusive and
somewhat controversial. Several reports implicate pannexin-1
hemichannels as mediators of the pore in mouse peritoneal macro-
phages. Others provide evidence that excludes a role for
pannexin-1 channels as the P2X7R pore in the same cells and
demonstrate that the P2X7R channel itself holds the capacity to
allow the passage of nanometer-sized particles, such as
YO-PRO-1 molecules, in P2X7R-transfected HEK-293 cells
(reviewed by [47]). It is speculated that P2X7R-driven
pore-mediated cell permeabilization could be facilitated by a num-
ber of different channels including the pannexins that can be
recruited to form the P2X7R pore and this will depend upon the
speciﬁc cell type and/or the type of inﬂammatory signal. Perhaps
during antigen presentation to T-cells, DC employ a more directly
targeted approach, such as the release of IL-1b loaded microvesi-
cles or exosomes to deploy a strong cytokine signal to a speciﬁc
cell.
5. Conclusions
Despite the many reports focusing on P2X7R activation and
IL-1b release, few have considered possible differences in
P2X7R-driven responses between different cell types. The results
of these investigations demonstrate that DC and macrophages dis-
play divergent patterns of cytokine expression, particularly with
respect to IL-1. ATP-mediated P2X7R activation offers an efﬁcient
platform for the processing and release of IL-1b although it may
not play a central role for all types of inﬂammatory responses. It
is becoming increasingly apparent that the P2X7R has distinct
physicochemical properties that are species, but also cell, speciﬁc.
Thus far, research has been directed disproportionately toward
macrophages and although DC and macrophages share the same
myeloid lineage and some overlapping functions, it is clear that
DC display distinct cell-speciﬁc properties with respect to P2X7R
function and the regulation of the release of pro-inﬂammatory
cytokines such as IL-1b. Understanding the cell-speciﬁc regulation
of such cytokines may pay dividends with respect to manipulating
such responses in health and disease.Acknowledgement
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